Relative Bioavailability study of D-0502 tablet formulation in healthy female subjects

Phase 1, Open Label, Randomized, Single dose, 3 Period, 3 treatment study to evaluation the relative Bioavailability of D-0502 tablet formulation in healthy female subjects

Inclusion Criteria:

• Healthy female subjects between the ages of 18-55
• Required evaluation by Investigator for screening and enrollment
• Agreement and compliance with the study and follow-up procedures

Exclusion Criteria:

• Significant medical history or current comorbidly determined by the Investigator.
• Pregnant or nursing women